Board of Directors - Vicore Pharma

Jacob Gunterberg

Chairman of the Board since 2022. Board member since 2018

Jacob Gunterberg is a former partner at HealthCap and has extensive experience in venture capital investment operations and corporate finance in life science. Jacob Gunterberg has long experience as board member in both private and publicly traded companies.

Shareholdings: 6,400

Share awards: –

Education: M.Sc. in Business Administration and Economics from Lund University.

Other assignments:Board member in EllAug AB, Tova Skrenen Stockholm AB, Aurelia Invest AB.

Independent of the company and its senior management but dependent of major shareholders of the company.

Heidi Hunter

Board member since 2020

Heidi Hunter (born 1958) has more than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. She has worked strategically and operationally from clinical and commercial development to launch execution. Her leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability. Heidi has a unique, multicultural and global experience of engaging people from different cultures to work towards the same vision and goals.

Holdings in Vicore: 5,000

Share awards: 175,000

Education: M.B.A., Marketing and International Business, The University of Chicago. ?B.A., Economics and German, Magna cum laude, The University of Michigan

Other assignments: SVP, Global Immunology Business Unit at UCB, Belgium.

Independent of the company and its senior management and independent of major shareholders of the company.

Maarten Kraan

Board member since 2018

Maarten Kraan has extensive experience in biomedicine and has, among others, held a senior position at AstraZeneca AB where he was responsible for the research and development of medicines for respiratory, inflammatory and autoimmune symptoms. Maarten is currently CMO at AM-Pharma a clinical stage Biotech.

Shareholdings: 4,025

Share awards: 20,591

Education: Doctor’s degree in rheumatology at the University of Leiden.

Other assignments: Maarten Kraan is a board member of Toleranzia AB and CDS Gmbh.

Independent of the company and its senior management and independent of major shareholders of the company.

Sara Malcus

Board member since 2018

Sara Malcus has more than ten years of experience from operational management and board work through her work with developing early drug projects at GU Ventures, Astra Zeneca AB and in smaller start-up companies.

Shareholdings: 2,902

Share awards: 20,591

Education: Doctor’s degree in immunology and inflammatory medicine at the University of Gothenburg.

Other assignments: Sara Malcus is the external Managing Director of MetaboGen AB.

Independent of the company and its senior management and independent of major shareholders of the company.

Hans Schikan

Board member since 2018

Mr. Schikan is former CEO of Prosensa (acquired by BioMarin). His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon (acquired by Schering Plough). He previously served on the boards of Hansa Biopharma, Asceneuron, Wilson Therapeutics (acquired by Alexion), Swedish Orphan Biovitrum, Sweden and Therachon (acquired by Pfizer).

Shareholdings: 4,000

Share awards: 20,591

Education: Pharmacist degree (PharmD) from the University of Utrecht.

Other assignments:Chairman of InteRNA Technologies BV, Microbiotica Ltd and Complix NV. Board member of VectivBio AG, Pharvaris NV and the Dutch Top Sector Life Sciences & Health. Advisor to various organisations in Life Sciences & Health.

Independent of the company and its senior management and independent of major shareholders of the company.